The estimated Net Worth of Maria C Freire is at least $4.61 Milion dollars as of 14 August 2024. Maria Freire owns over 8,250 units of Exelixis Inc stock worth over $2,423,516 and over the last 13 years he sold EXEL stock worth over $1,737,951. In addition, he makes $448,227 as Independent Director at Exelixis Inc.
Maria has made over 6 trades of the Exelixis Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he sold 8,250 units of EXEL stock worth $219,120 on 14 August 2024.
The largest trade he's ever made was selling 8,275 units of Exelixis Inc stock on 11 May 2021 worth over $206,958. On average, Maria trades about 805 units every 83 days since 2012. As of 14 August 2024 he still owns at least 91,007 units of Exelixis Inc stock.
You can see the complete history of Maria Freire stock trades at the bottom of the page.
Dr. Maria C. Freire Ph.D. serves as Independent Director of the Company. Maria C. Freire, Ph.D., has been a director since April 2018. Since November 2012, Dr. Freire has served as President and Executive Director and as a member of the board of directors of the Foundation for the National Institutes of Health. From March 2008 to November 2012, she served as President and as a member of the board of directors of the Albert and Mary Lasker Foundation. Prior to joining the Lasker Foundation, Dr. Freire served as President and Chief Executive Officer of the Global Alliance for TB Drug Development from 2001 to 2008 and Director of the Office of Technology Transfer at the National Institutes of Health from 1995 to 2001. Dr. Freire has served on the board of directors of Alexandria Real Estate Equities, Inc. a publicly held urban office real estate investment trust uniquely focused on collaborative life science and technology campuses, since April 2012, and has served on the boards of numerous national and international organizations, including the Science Board of the U.S. Food and Drug Administration, the World Health Organization Commission on Intellectual Property Rights, Innovation and Public Health and the United Nations Secretary General’s High Level Panel on Access to Medicines. Dr. Freire is also a member of the National Academy of Medicine and the Council on Foreign Relations, and she is the recipient of numerous awards, including a 2017 Gold Stevie Award for “Woman of the Year,” the U.S. Department of Health and Human Services Secretary’s Award for Distinguished Service, the Arthur S. Fleming Award and the Bayh-Dole Award. Dr. Freire holds a Ph.D. in Biophysics from the University of Virginia and a B.S. from the Universidad Peruana Cayetano Heredia in Lima, Peru.
As the Independent Director of Exelixis Inc, the total compensation of Maria Freire at Exelixis Inc is $448,227. There are 16 executives at Exelixis Inc getting paid more, with Dr. Michael M. Morrissey having the highest compensation of $2,349,812.
Maria Freire is 65, he's been the Independent Director of Exelixis Inc since 2018. There are 6 older and 15 younger executives at Exelixis Inc. The oldest executive at Exelixis Inc is Vincent Marchesi, 84, who is the Independent Director.
Maria's mailing address filed with the SEC is C/O EXELIXIS, INC., 1851 HARBOR BAY PARKWAY, ALAMEDA, CA, 94502.
Over the last 23 years, insiders at Exelixis Inc have traded over $82,392,913 worth of Exelixis Inc stock and bought 1,847,609 units worth $19,175,184 . The most active insiders traders include Jean Francois Formela, Michael Morrissey oraz Stelios Papadopoulos. On average, Exelixis Inc executives and independent directors trade stock every 12 days with the average trade being worth of $898,709. The most recent stock trade was executed by Jeffrey Hessekiel on 26 August 2024, trading 20,000 units of EXEL stock currently worth $488,200.
exelixis is a biopharmaceutical company focused on developing and commercializing small molecule therapies with the potential to improve the treatment of cancer. over the past decade, we have established a broad development platform, laying the foundation for our continued efforts to bring new therapies for cancer to patients in need. our first commercial product, cometriq® (cabozantinib), received its initial regulatory approval in late 2012. we are committed to excellence in all aspects of our business and are dedicated to improving the care of, and outcomes for, patients with cancer. for more information about the company and potential job opportunities, please visit our website at www.exelixis.com.
Exelixis Inc executives and other stock owners filed with the SEC include: